BPC-157 is a synthetic peptide of 15 amino acids based on a protein found in human stomach juice.[2] It has become one of the most popular “healing peptides” for tendon, muscle and gut injuries because of strong results in rats.[1] In people, though, a 2026 review counted fewer than 30 participants across three small uncontrolled studies,[17] and BPC-157 is not FDA-approved.[7]
This profile covers what BPC-157 is, how it works, what the animal and human research shows, who is behind that research, side effects, oral vs injected use, doses studied and the regulatory picture.
What is BPC-157?
BPC-157 stands for “Body Protection Compound 157”. Its sequence (GEPPPGKPADDAGLV) was developed by Predrag Sikiric’s group at the University of Zagreb, Croatia, from a protein in gastric juice.[9][2] It was tested under the names PL 14736 (by Croatian drugmaker Pliva) and Bepecin.[9][29]
FDA notes that BPC-157 has no official drug name, and that different salts and forms are sold under the same name.[7]
How BPC-157 works
Lab and animal studies suggest several mechanisms:
- Blood vessel growth: BPC-157 increased blood vessel formation and blood flow recovery in rats, by switching on VEGFR2 and nitric oxide signaling.[12]
- Tendon cells: in Taiwanese studies, it helped tendon cells survive stress and migrate, and increased their growth hormone receptors, though it did not directly make them multiply.[10][11]
- Human tissue: in arteries removed during heart bypass surgery in Türkiye, BPC-157 relaxed the vessels through nitric oxide; the authors called this early evidence.[13]
FDA’s 2026 review notes that its precise molecular targets have not been identified.[7]
BPC-157 benefits: what the research shows
In animals
A 2025 systematic review found 36 studies of BPC-157 for muscle, tendon, ligament and bone; 35 were in animals, and they consistently showed benefits.[1] In rats with a cut Achilles tendon, it improved strength, function and tissue structure.[3] Chinese researchers found it sped healing of chemical burns in rats.[35]
In people
| Study | Who | What happened |
|---|---|---|
| Knee injections (chart review) | 16 patients | 14 reported improvement; no control group or validated scoring[4] |
| Bladder pain (interstitial cystitis) | 12 women | 10 reported complete relief after one injection; no control group[5] |
| IV safety pilot | 2 adults | No measurable changes in safety tests[6] |
| Ulcerative colitis enemas (Croatia) | 53 patients | Did not clearly beat placebo; never fully published[7] |
Who is behind the research
More than 80% of the roughly 190 BPC-157 papers on PubMed list members of the original Zagreb group as first or senior author.[19] An Undark/STAT investigation reported that the group’s leader is named on BPC-157 patents going back to at least 1989 and is linked to companies developing it, and that these ties were not disclosed in the papers it reviewed.[31] Independent replication is limited.
BPC-157 and TB-500 together
BPC-157 is often stacked with TB-500, including in the GLOW and KLOW blends. The only study of the combination, in rats in Türkiye, found that combining them gave no additional benefit for tendon healing over either alone.[16]
Oral BPC-157 vs injection
BPC-157 is unusually stable in stomach juice, which is why capsules are sold.[17] The Croatian ulcerative colitis trials used enemas, and a 2015 oral tablet trial was registered but never reported results.[7][34] However, no oral product has been developed and validated to pharmaceutical standards.[17]
Claims that “arginate” or “stable” salts are absorbed far better come from sellers; we found no published studies supporting them. Injected BPC-157 lasts less than 30 minutes in the blood of rats and dogs.[15]
BPC-157 research around the world
- Croatia: the original research group and early clinical trials for inflammatory bowel disease.[9]
- Taiwan: independent studies at Chang Gung University on tendon cells and blood vessels.[10][11][12]
- China: a 2020 toxicology study in four animal species called it well tolerated[14], and a pharmacokinetic study measured its short half-life[15].
- Türkiye: the human artery study and the BPC-157 plus TB-500 rat study.[13][16]
- United States: a University of Arkansas randomized trial after rotator cuff surgery is registered to start in 2027.[33]
BPC-157 side effects and safety
- Small human studies: no serious side effects were reported, but monitoring was limited. Healthy volunteers given BPC-157 enemas most often reported headache and gas.[7]
- FDA reports: FDA described reports of injection-site redness and swelling, shortness of breath leading to an ER visit, and skin and gum darkening when used with TB-500; causes were unclear.[7]
- Journalism reports: KFF Health News described people reporting months of fatigue and anxiety, or severe migraine, after using BPC-157 from online sellers; these are individual accounts, not proof of cause.[32]
- Animal toxicology: a 2020 Chinese toxicology study called it well tolerated[14], but FDA read the data as showing possible blood-clotting and liver signals[7].
- Theoretical cancer risk: because BPC-157 promotes blood vessel growth, Cleveland Clinic and review authors describe a theoretical concern that it could help existing cancers grow. No study has tested this directly.[30][18][22]
- Product quality: research-use-only products may be contaminated or mislabeled.[30][23]
BPC-157 dosage: what has been studied
No dose of BPC-157 is approved, and safe dose limits are unknown.[30]
| Setting | Dose |
|---|---|
| Bladder injection pilot | Single 10 mg injection[5] |
| IV safety pilot | 10 mg, then 20 mg[6] |
| Rat tendon study | 10 micrograms to 10 picograms per kg per day[3] |
For converting milligrams to syringe units, see our peptide calculator.
What users report
Is BPC-157 FDA approved or legal?
- Not FDA-approved and not part of any approved drug.[7]
- 2023: FDA listed BPC-157 among substances that may present significant safety risks in compounding.[23]
- April 2026: after the nominations were withdrawn, FDA removed it from that list, which is not an approval.[23][24]
- July 2026: FDA reviewed BPC-157 for ulcerative colitis and recommended against it, but its advisory committee reportedly voted 8 to 6 in favor.[25][8][26] The vote is not binding, and no rule had followed as of our last review.
- Not a supplement: the Department of Defense calls BPC-157 an unapproved drug that is not a legal dietary ingredient.[29]
- Banned in sport: WADA prohibits BPC-157 at all times as a non-approved substance.[27][28]
This is general information, not legal advice.